Taiwan Advance Bio-Pharmaceutical Inc. (4186.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$6.70 (-5.63%) as of
Key statistics
- Market cap
- 603.00M
- P/E (TTM)
- 39.41
- EPS (TTM)
- 0.17
- Dividend yield
- 0.00%
- 52-week range
- 6.65 – 13.85
- Beta
- 0.32
- Revenue (TTM)
- 348.54M
- Profit margin
- 4.52%
- Volume
- 201.76k
About Taiwan Advance Bio-Pharmaceutical Inc.
Taiwan Advance Bio-Pharmaceutical Inc. operates in the biotechnology industry in China, Germany, USA, Italy, Malaysia, Vietnam, Thailand, Indonesia, Japan, Korea, India, Pakistan, and internationally. The company provides food safety diagnostic testing kits; ELISA and rapid test kits customization, and food safety lab establishment consultation services; and manufactures monoclonal and polyclonal antibody products. It also offers stem cell banking services for newborn and adult stem cells storage; cell therapy programs; abused drugs rapid tests; operates drug testing center for urine drug test, hair drug test, and identification of drug abuse. The company also involves in research, development, production, and sales of veterinary drug residue testing reagents, drug abuse certification testing services and management, detection, extraction, cryopreservation and storage, and gene testing services for umbilical cord blood stem cells, umbilical cord mesenchymal stem cells, peripheral blood stem cells, and related businesses. Taiwan Advance Bio-Pharmaceutical Inc. was founded in 1989 and is based in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
- Employees
- 160
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.